- 89% of patients tested were (very) satisfied with the convenience of the Pen
- 94% of patients tested were (very) satisfied with the efficacy of the Pen
- 82% of all patients tested prefer Wartner Wart Pen over their current treatment
What clinical data do we have?
In today’s market place of the UK/Europe, acid based products are using salicylic acid as an active ingredient. These products form an acid layer that induces the chemical peeling of the wart tissue. Typically, salicylic acid products require constant renewal of the application. SPCs of these products tends to always indicate a treatment time up to 12 weeks with daily usage.
Contrary to today’s market standards, the new Wartner Wart Pen uses TCA (trichloroacetic acid) as active ingredient. TCA is recognized to be a stronger acid (more corrosive & higher concentration in the pen itself) making the peel off action of the wart tissue ongoing, resulting in a faster removal of the wart/verruca.
Pilot clinical study:
Tested in a self assessed study, 55% of people assessed had a complete removal of their wart/verruca in just 1 week, clearly indicating that first visible results are reached within the first treatment period of 4 days.
Full clinical study based on Dermatology standards:
A in-vivo clinical study based on dermatology standards (expert assessed) has been performed to assess the efficacy of the Wartner Pen. Up to 65% of all warts treated with the Wartner Pen was removed after just 4 weeks, and the first effects (keratinisation and peeling off of skin) were already visible after the first week of treatment. These results are superior to the scientific literature on conventional liquids and gels which indicate a treatment time of about 12 weeks (as per SPCs) resulting in wart/verruca removal in 52% of patients tested.
Product satisfaction questionnaire:
A product satisfaction questionnaire was included assessing product compatibility, convenience & efficacy. Main highlights: